MetaCap

BioVie (BIVI) vs Moleculin Biotech (MBRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie is the larger company by market cap ($8.6 million vs $8.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIVI-42.86%MBRX+1663.50%
+2114%+984%-146%
Oct 7, 20261 yearNov 20, 2026
BIVI-42.45%MBRX+1651.13%
+1964%+913%-138%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIVI versus MBRX key metrics
MetricBIVIMBRX
Share price$0.80$7.74
Market cap$8.58M$8.22M
1-day change-12.07%-2.40%
YTD return-31.03%—
1-year return-38.22%—
5-year return-99.87%—
P/E ratio (TTM)—0.04
EPS (TTM)$-2.85$179.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-22.07M$-33.56M
52-week high$3.79$202.50
52-week low$0.7515$3.22
Distance from 52-week high-78.89%-96.18%
Analyst consensusnonestrong_buy
Avg. price target upside+557.50%+55.04%
Average volume568.61K44.66K
Shares outstanding10.72M1.06M
Employees1317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

BIVI vs MBRX FAQ

Which is bigger, BioVie or Moleculin Biotech?

BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.22M for Moleculin Biotech (MBRX).

Are BioVie and Moleculin Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons